Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc.

IMDX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$70.03M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Insight Molecular Diagnostics Inc.Insight Molecular Diagnostics Inc.-1.4-174%--0.1
$1.00

Target Price by Analysts

49.2% downsideInsight Molecular Diagnostics Target Price DetailsTarget Price

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$70.03 Million
Enterprise Value$61.20 Million
Earnings per Share$-1.65
Beta1.86
Outstanding Shares36,750,000

Return

Return on Equity174.07%ROE
Return on Assets-193.56%
Return on Invested Capital-351.02%

Valuation & Multiples

P/E Ratio-1.41P/E Ratio
PEG2.1PEG
Price to Sales-Price to Sales
Price to Book Ratio-1.97Price to Book Ratio
Enterprise Value to Revenue31.08
Enterprise Value to EBIT-1.43
Enterprise Value to Net Income-2
Total Debt to Enterprise0.04
Debt to Equity-0.09Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 16, 2026
EPS
-$0.10
Est. -$0.24
Revenue
$559,000
Est. $244,280

Next Earnings Call

Expected Date
April 1, 2027
EPS Estimate
-$0.21
Consensus analyst estimate
Revenue Estimate
$553,720
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %12.40%▼ 37.84%
Total Invested$16.36M▼ 84.98%
Investors Holding28▼ 13.00%

About OncoCyte Corp

57 employees
CEO: Joshua Riggs

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the Uni...